Report Code: A13195 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Gastroretentive drug delivery refers to approaches, formulation, manufacturing technique, storage systems, and technologies involved in transporting a pharmaceutical compound to its targeted site in gastro intestinal tract to achieve desired effect. Principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are used to increase potency and safety of drug delivery system. The prevention and management of the disorder can be achieved by enhancing mucosal protection by gastroretentive drug delivery system. This system is used to advance oral delivering of drugs in the upper gastro intestinal tract can enhance oral bioavailability as well as therapeutic outcome.
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the gastroretentive drug delivery system market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In 2020, Cadila Pharmaceuticals announced launch Esomeprazole tablets. This tablets are used in treatment of hyperacidity & drug induced gastritis.
In 2020, Xiromed LLC launched 20mg Omperazole delayed release capsules. Omeprazole is cost effective generic product which can be used in treatment of gastroesophageal reflux disease and healing of erosive esophagitis.
Key Benefits of the Report
Questions Answered in the Gastroretentive Drug Delivery System Market Report
Gastroretentive Drug Delivery System Market Report Highlights
Aspects | Details |
---|---|
By Dosage Form |
|
By Type |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | GlaxoSmithKline, Alcon Inc., Pharmacia, Novartis AG, Sun Pharmacautical, F. Hoffmann La Roche, Depomed Inc., Ranbaxy Laboratories, Galanix Co., Lupin Ltd |
Loading Table Of Content...
Start reading.
This Report and over 71,323+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers